IDEXX publishes investor day presentation on diagnostics innovation, software and AI growth strategy
IDXX•R&D and platform expansion
The presentation cited more than USD 2.5 billion in R&D investment, including USD 1.3 billion in software, data, AI, and connectivity.
It also emphasized new platforms and menu expansion, including MultiCue Dx, inVue Dx, Catalyst expansions, and broader Cancer Dx coverage.
Business metrics highlighted
IDEXX highlighted 97% recurring revenue retention in its CAG Diagnostics business, 99% product availability, and a brand Net Promoter Score of 64.
Investor day strategy and long-term targets
IDEXX outlined a strategy built on diagnostics innovation, software, AI, connectivity, and international expansion to drive long-term growth.
The company said its long-term model targets 10%+ organic revenue growth with high ROIC, supported by a stated USD 45 billion+ veterinary testing opportunity.
